Teva Pharmaceutical Industries Limited
5 Basel Street
PO Box 3190
Petach Tikva,
49131
Israel - Map
Phone: 972 3 926 7267
Fax: 972 3 923 4050
Web Site: http://www.tevapharm.com
| Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its research and development efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune diseases, and oncology. The companys principal products include Copaxone for multiple sclerosis; and Azilect for Parkinsons disease. Teva Pharmaceutical also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; and Cyclohaler, a single dose dry powder device. The companys branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory products, dermatological hormones, anti-inflammatories, oncolytics, immunosuppressants, and muscle relaxants, as well as custom-manufactured APIs for various proprietary drug manufacturers. Teva Pharmaceutical added women's health portfolio to its specialty pharmaceutical platform through the acquisition of Barr Pharmaceuticals Inc. The company also holds a biotechnology platform focused on the development of peptide and protein-based medicines through the ownership of CoGenesys, Inc., a biopharmaceutical company. It has a collaboration agreement with Optimata Ltd. to develop solid tumor cancer drugs; a strategic alliance with Kowa Company, Ltd. to establish a generic pharmaceutical company in Japan; and a strategic partnership with the Lonza Group in a joint venture to develop, manufacture, and market a portfolio of biogenerics. The company was founded in 1901 and is headquartered in Petach Tikva, Israel. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Shlomo Yanai , 57
Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Eyal Desheh , 58
Chief Financial Officer |
N/A
| N/A | Mr. William S. Marth , 55
Chief Exec. Officer of Teva North America, Chief Exec. Officer of Teva Pharmaceuticals USA, Pres of Teva North America and Pres of Teva Pharmaceuticals USA |
N/A
| N/A | Mr. Gerard Van Odijk , 52
Group VP of Europe Operations, Chief Exec. Officer of Teva Pharmaceutical Europe B V and Pres of Teva Pharmaceutical Europe B V |
N/A
| N/A | Dr. Ben-Zion Weiner Ph.D., 65
Chief Research & Developement Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
